Carter Thomas J, Jeyaneethi Jeyarooban, Kumar Juhi, Karteris Emmanouil, Glynne-Jones Rob, Hall Marcia
Mount Vernon Cancer Centre, Middlesex HA6 2RN, UK.
Department of Life Sciences, Brunel University, London UB83PH, UK.
Cancers (Basel). 2020 Aug 10;12(8):2229. doi: 10.3390/cancers12082229.
Whilst anal cancer accounts for less than 1% of all new cancer cases, incidence rates have increased by up to 70% in the last 30 years with the majority of cases driven by human papilloma virus (HPV) infection. Standard treatment for localised anal cancer is chemoradiotherapy (CRT). Localised progression is the predominant pattern of relapse but well under 50% of cases are salvaged by surgery, predominantly because confirming recurrence within post-radiation change is very challenging. Identifying cancer-associated circulating cells (CCs) in peripheral blood could offer a corroborative method of monitoring treatment efficacy and identifying relapse early. To study this, nucleated cells were isolated from the blood of patients with anal cancer prior to, during, and after CRT and processed through the Amnis ImageStreamX Mk II Imaging Flow Cytometer, without prior enrichment, using Pan-cytokeratin (PCK), CD45 antibodies and making use of the DNA dye DRAQ5. Analysis was undertaken using IDEAS software to identify those cells that were PCK-positive and DRAQ5-positive as well as CD45-negative; these were designated as CCs. CCs were identified in 7 of 8 patients; range 60-876 cells per mL of blood. This first report of the successful identification of CCs in anal cancer patients raises the possibility that liquid biopsies will find a future role as a prognostic/diagnostic tool in this patient group.
虽然肛管癌占所有新发癌症病例的比例不到1%，但在过去30年中，发病率增长了高达70%，大多数病例是由人乳头瘤病毒（HPV）感染引起的。局部肛管癌的标准治疗方法是放化疗（CRT）。局部进展是复发的主要模式，但只有不到50%的病例能通过手术挽救，主要原因是在放疗后改变中确认复发非常具有挑战性。在外周血中识别癌症相关循环细胞（CCs）可以提供一种辅助方法来监测治疗效果并早期识别复发。为了研究这一点，在放化疗前、期间和之后，从肛管癌患者的血液中分离有核细胞，并通过Amnis ImageStreamX Mk II成像流式细胞仪进行处理，无需事先富集，使用全细胞角蛋白（PCK）、CD45抗体并利用DNA染料DRAQ5。使用IDEAS软件进行分析，以识别那些PCK阳性、DRAQ5阳性且CD45阴性的细胞；这些细胞被指定为CCs。在8名患者中的7名患者中识别出了CCs；每毫升血液中CCs的数量范围为60 - 876个。这篇关于在肛管癌患者中成功识别CCs的首次报告提出了液体活检在该患者群体中作为一种预后/诊断工具发挥未来作用的可能性。
